| Next 10 |
GBT News and Press, Global Blood Therapeutics Inc.
-
Global Blood Therapeutics (NASDAQ:GBT) may be a potential acquisition candidate in the biotech space following Pfizer (PFE)'s deal to acquire Biohaven Pharmaceutical for about $11.6 billion, according to a Wedbush analyst. "In light of Pfizer’s $12 billion acquisition of Biohaven Pharm...
-
New real-world evidence data on Oxbryta ® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASD...
-
After market hours on Wednesday, Global Blood Therapeutics (NASDAQ: GBT) released a first-quarter earnings report that investors didn't digest well. As a result, the following day, the stock fell by 8% -- a steep rate, even on a very bearish day when the S&P 500 index declin...
-
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript ...
-
Global Blood Therapeutics, Inc. (GBT) Q1 2022 Earnings Conference Call May 04, 2022 4:30 PM ET Company Participants Steven Immergut – Senior Vice Preside, Head-Corporate Communications and Investor Relations Ted Love – President and Chief Executive Officer Jeff Farrow – C...
-
Global Blood Therapeutics press release (NASDAQ:GBT): Q1 GAAP EPS of -$1.26 beats by $0.06. Revenue of $55.16M (+41.3% Y/Y) misses by $0.97M. For further details see: Global Blood Therapeutics GAAP EPS of -$1.26 beats by $0.06, revenue of $55.16M misses by $0.97M
-
Achieved Oxbryta ® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patients ages 12 y...
-
Global Blood Therapeutics (NASDAQ:GBT) is scheduled to announce Q1 earnings results on Wednesday, May 4th, after market close. The consensus EPS Estimate is -$1.36 and the consensus Revenue Estimate is $56.13M (+43.8% Y/Y). Over the last 1 year, GBT has beaten EPS estimates 25% of the time an...
-
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to meeting the needs of underserved patient communities starting with sickle cell disease (SCD), today released its inaugural environm...
-
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Management will host a con...
Stock Information
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
MENU
GBT
GBT Quote
GBT Short
GBT News
GBT Articles
Get GBT Alerts
News, Short Squeeze, Breakout and More Instantly...
-
New real-world evidence data on Oxbryta ® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASD...
-
After market hours on Wednesday, Global Blood Therapeutics (NASDAQ: GBT) released a first-quarter earnings report that investors didn't digest well. As a result, the following day, the stock fell by 8% -- a steep rate, even on a very bearish day when the S&P 500 index declin...
-
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript ...